Korean J Med.  2008 Apr;74(4):366-367.

Systemic drug therapy and restenosis after drug-eluting stent implantation

Affiliations
  • 1Department of Internal Medicine, College of Medicine, Hallym University, Seoul, Korea.

Abstract

Until now restenosis is one of the most important issues after stent implantation. Use of systemic drug therapy to inhibit post-stent restenosis has been largely unsuccessful. Drug-eluting stents (DES) have been shown to significantly reduce restenosis after percutaneous coronary intervention. However we still experience lots of problems associated with restenosis even after DES implantation. Recently some clinical trials have suggested that cilostazol reduces intimal hyperplasia and lowers restenosis after bare metal stents (BMS) implantation. It is uncertain that cilostazol can also reduce restenosis after DES implantation. We need more large clinical trials to elucidate the efficacy of cilostazol on restenosis after DES implantation.

Keyword

Drug-eluting stent; Restenosis; Systemic drug therapy; Cilostazol

MeSH Terms

Drug-Eluting Stents
Hyperplasia
Percutaneous Coronary Intervention
Stents
Tetrazoles
Tetrazoles
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr